Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23123431 | 0.77 | NAAA (0.32) | — | |
| SCHEMBL18612421 | 0.77 | AGTR2 (0.32) | AGTR2P2RX7 | |
| SCHEMBL23123714 | 0.77 | NAAA (0.32) | — | |
| SCHEMBL6806230 | 0.72 | NAAA (0.33) | ACE | |
| SCHEMBL2712732 | 0.69 | ACE (0.56) | ACEITGB1ITGA5P2RX7 | |
| SCHEMBL2715722 | 0.69 | ACE (0.56) | ACEITGB1ITGA5P2RX7 | |
| SCHEMBL2805870 | 0.69 | ACE (0.56) | ACEITGB1ITGA5P2RX7 | |
| SCHEMBL1190522 | 0.67 | P2RX7 (0.58) | AGTR2ACEP2RX7 | |
| SCHEMBL23452178 | 0.67 | ITGB1 (0.38) | ACEITGB1ITGA5 | |
| SCHEMBL23452176 | 0.67 | ITGB1 (0.38) | ACEITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | ALPI, ASAH2, STS | AGTR2 215/4885ACE 60/4885ITGB1 4582/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | AGTR2 73/4885ACE 55/4885ITGB1 3958/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | AGTR2 215/4885ACE 60/4885ITGB1 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.